Recipelist

Alvegesic Vet 10 mg/ml 10 ml

Haftungsausschluss: Produkt auf dem Foto kann vom tatsächlichen Produkt abweichen.

SKU
10404
Hersteller:
VMD
Batch:
24052370
Haltbarkeitsdatum:
31-08-2027
Registrierungsnummer:
NL: REG NL 101772 UDD - BE: VE-V340575

Ist die Registrierungsnummer Ihres Landes nicht sichtbar? Dann handelt es sich um ein Kaskadenprodukt. Klicken Sie hier für weitere Informationen.

Solution for injection for horses, dogs and cats

HORSE

As analgesic: for the management of moderate to severe abdominal pain (relieves abdominal pain associated with colic that is of gastrointestinal origin).

As a sedative: for sedation after administration of certain alpha-2-adrenoceptor agonists (detomidine, romifidine).

Gebrauchsanweisung

Solution for intravenous use (IV). To ensure correct dosing, body weight should be determined as accurately as possible.

For analgesia
The analgesic effect is observed within 15 minutes after injection and persists for about 2 hours.

 

Route of administration Dose of butorphanol mg/kg body weight Dosis Alvegesic vet. 10 mg/ml ml/kg body weight Note
IV 0,10 0,01 ml The dose may be repeated after 3-4 hours. Treatment should not exceed 48 hours. 

Active ingredient: butorphanol 10 mg/ml (equivalent to butorphanol tartrate 14,58 mg).

Additional ingredients: Benzethonium chloride 0,10 mg/ml, Citric acid monohydrate, Sodium citrate, Sodium chloride, Water for injection.

Tierärztlicher Hinweis

Combination butorphanol/detomidine hydrochloride:

  • Not safe for the treatment of mares during gestation.
  • Do not use in horses with pre-existing cardiac arrhythmia or bradycardia.
  • The combination causes a decrease in gastrointestinal motility and should therefore not be used in cases of colic caused by impaction.
  • Due to a possible negative effect on the respiratory system, the veterinary medicine is contraindicated for use in horses with emphysema.

Combination butorphanol/romifidine:

  • This combination should not be used during the last month of gestation.

Use of the veterinary medicinal product at the recommended dosage may cause transient ataxia and/or excitation. Therefore, the place of treatment should be carefully chosen to avoid injuries to patient and persons during equine treatment.

Merkblatt

SPC (NL)

© 2024 Grovet B.V. All rights reserved.